Skip to content

Exploration of Microcirculatory Alteration and Endothelial Dysfunction by Adaptive Optics in Multiple Sclerosis

Exploration of Microcirculatory Alteration and Endothelial Dysfunction by Adaptive Optics in Multiple Sclerosis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03508089
Acronym
MS-EYE
Enrollment
60
Registered
2018-04-25
Start date
2017-08-22
Completion date
2018-06-30
Last updated
2018-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sclerosis, Multiple

Brief summary

It's a pilot, interventional prospective monocentric study. It aims to compare the wall / lumen ratio (WLR) of retinal arterioles (common marker of microangiopathies) between patients with multiple sclerosis and controls using the technique of adaptive optics.

Interventions

OTHEROcular fundus on patient with Multiple Sclerosis

Ocular fundus on patient with Multiple Sclerosis

OTHEROcular Fundus on voluntary person

Ocular Fundus on voluntary person

Sponsors

Versailles Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

Patient Inclusion Criteria * Major patient between 18 and 50 years * Patient with relapsing or remitting multiple sclerosis defined according to revised Mc Donald criteria 2010 * Written, free and informed consent dated and signed * Patient affiliated to a social security scheme Control Inclusion Criteria: * Person between the ages of 18 and 50 * Written, free and informed consent dated and signed * Person affiliated to a social security scheme * Person with multiple sclerosis

Exclusion criteria

* Contraindication to the use oxygen (O2): Acute or chronic respiratory insufficiency * Pregnant or lactating woman * Inability to see fundus (cataract), retinopathy, glaucoma * Use of vasoactive substances (eg nasal decongestants, triptans, alkaloids) in the last 48 hours * Use of nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, ..) and steroids (corticosteroids) in the last 48 hours * Known Diabetes or taking antidiabetics in the last 48 hours * Use of statins in the last 48 hours * Known hypertension or antihypertensive treatment in the last 48 hours * Any cardiac pathology (valvulopathy, angina, ventricular arrhythmia or atrial fibrillation), vascular (arteritis obliterating the lower limbs, stenosis of the arteries with encephalic destiny, coronary artery disease) or significant respiratory (asthma, Chronic obstructive pulmonary disease, interstitial pathology) * Alcohol consumption within 8 hours * Ophthalmoparesis or incapacitating nystagmus (impossibility of correctly evaluating the fundus)

Design outcomes

Primary

MeasureTime frame
To compare the wall / lumen ratio (WLR) of retinal arterioles (common marker of microangiopathies) between multiple sclerosis patients and controls using the adaptive optics technique.Day 0

Secondary

MeasureTime frame
Compare between patients with multiple sclerosis and controls, retinal arteriolar gauges measured by external and internal diameter.Day 0
Correlate possible changes in arteriolar WLR with internal and external diameter, smoking, age, blood pressure, fatigue (MFIS), cognition (MDT) and disability (EDSS) scores to ambient air and normobaric oxygen.Day 0

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026